In the KEYNOTE-024 and KEYNOTE-042 phase III clinical trials, programmed cell death protein 1 (PD-1)-targeted immunotherapy significantly improved the overall survival (OS) rate compared with standard therapy in advanced NSCLC (2, 3). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.